NCT00397215 - Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age | Biotech Hunter

Enrollment

437

Participants

Timeline

Start Date

November 17, 2006

Primary Completion Date

September 14, 2009

Study Completion Date

September 14, 2009

Conditions

Influenza

Interventions

BIOLOGICAL

Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)

intramuscular injection

BIOLOGICAL

Fluarix

Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.

Trial Locations (12)

1170

GSK Investigational Site, Watermael-Boitsfort

3980

GSK Investigational Site, Tessenderlo

4140

GSK Investigational Site, Sprimont

5530

GSK Investigational Site, Mont-Godinne

6534

GSK Investigational Site, Gozée

6800

GSK Investigational Site, Libramont

7370

GSK Investigational Site, Dour

16132

GSK Investigational Site, Genoa

20127

GSK Investigational Site, Milan

97100

GSK Investigational Site, Ragusa

09042

GSK Investigational Site, Monserrato Cagliari

07100

GSK Investigational Site, Sassari